In the last trading session, 1.57 million Applied Dna Sciences Inc (NASDAQ:APDN) shares changed hands as the company’s beta touched 0.78. With the company’s per share price at $1.83 changed hands at -$0.43 or -19.03% during last session, the market valuation stood at $2.02M. APDN’s last price was a discount, traded about -28424.59% off its 52-week high of $522.00. The share price had its 52-week low at $1.95, which suggests the last value was -6.56% down since then. When we look at Applied Dna Sciences Inc’s average trading volume, we note the 10-day average is 0.34 million shares, with the 3-month average coming to 102.68K.

Analysts gave the Applied Dna Sciences Inc (APDN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended APDN as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Applied Dna Sciences Inc’s EPS for the current quarter is expected to be -3.0.

Applied Dna Sciences Inc (NASDAQ:APDN) trade information

Instantly APDN was in red as seen at the end of in last trading. With action -73.65%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -82.06%, with the 5-day performance at -73.65% in the red. However, in the 30-day time frame, Applied Dna Sciences Inc (NASDAQ:APDN) is -78.99% down. Looking at the short shares, we see there were 60080.0 shares sold at short interest cover period of 1.58 days.

The consensus price target for the stock as assigned by Wall Street analysts is 1.5, meaning bulls need a downside of -22.0% from its current market value. According to analyst projections, APDN’s forecast low is 1.5 with 1.5 as the target high. To hit the forecast high, the stock’s price needs a 18.03% surge from its current level, while the stock would need to tank 18.03% for it to hit the projected low.

Applied Dna Sciences Inc (APDN) estimates and forecasts

Year-over-year growth is forecast to reach 53.99% up from the last financial year.

Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of 1.19M. 1 analysts are of the opinion that Applied Dna Sciences Inc’s revenue for the current quarter will be 1.28M. The company’s revenue for the corresponding quarters a year ago was 929.63k and 797.52k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 27.47%. The estimates for the next quarter sales put growth at 60.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 60.68%. The 2025 estimates are for Applied Dna Sciences Inc earnings to increase by 73.63%.

APDN Dividends

Applied Dna Sciences Inc is expected to release its next quarterly earnings report on 2025-Feb-12.

Applied Dna Sciences Inc (NASDAQ:APDN)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 19.47% of Applied Dna Sciences Inc shares while 26.90% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 33.41%. There are 26.90% institutions holding the Applied Dna Sciences Inc stock share, with MATHER GROUP, LLC. the top institutional holder. As of 2024-06-30, the company held 0.0803% of the shares, roughly 700.0 APDN shares worth $287.0.

JPMORGAN CHASE & CO holds the second largest percentage of outstanding shares.